The EFHD1 Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the EFHD1 gene in the human Huh-7 hepatocellular carcinoma cell line. This gene-targeted pool provides a heterogeneous loss-of-function model suitable for studying the functional roles of EFHD1 in apoptosis regulation, mitochondrial dynamics, and inflammatory signaling pathways. The polyclonal format allows researchers to assess overall gene disruption effects without the constraints of single-cell clonal selection, offering a practical approach for initial functional screenings.
Huh-7 cells are a widely utilized human hepatocellular carcinoma cell line originally established from a liver tumor. These adherent, tumorigenic liver epithelial cells retain key hepatocyte features and are extensively employed in liver cancer research to investigate oncogenic mechanisms, drug metabolism, and signaling cascades. Their well-characterized genetic background and responsiveness to apoptotic stimuli make them an ideal host for knockout studies, particularly for dissecting pathways involved in cell survival and death.
EFHD1 encodes a calcium-binding mitochondrial protein that plays a critical role in the intrinsic apoptosis pathway and NF-??B signaling. Mechanistically, EFHD1 modulates mitochondrial permeability transition pore (mPTP) activity and cytochrome c release, acting as an anti-apoptotic factor. It directly interacts with VDAC1 at the mitochondrial outer membrane and with IKK?? in the NF-??B pathway, suppressing IKK??-mediated phosphorylation and subsequent nuclear translocation of p65. Under conditions of cellular stress or calcium influx, EFHD1 impacts the balance of Bcl-2 family proteins, thereby regulating caspase-9 and caspase-3 activation. Its dual function in mitochondria and NF-??B signalosome positions it at a key regulatory node.
In the context of hepatocellular carcinoma, EFHD1 disruption is particularly relevant as liver cancer cells often exhibit heightened resistance to apoptosis and constitutive NF-??B activity, both contributing to tumor progression and therapy resistance. Knockout of EFHD1 in Huh-7 cells enables the study of how loss of this protein sensitizes cells to apoptotic stimuli and dampens NF-??B-mediated pro-survival gene expression. This model is ideal for exploring the interplay between mitochondrial calcium handling, apoptotic signaling, and inflammatory pathways in a liver cancer background.
Applications for these knockout cells include mechanistic studies of mitochondrial apoptosis using assays such as Annexin V/PI staining, caspase-3/9 activity measurements, and cytochrome c release detection. They can be employed in NF-??B reporter assays with luciferase-based readouts and in drug screening campaigns to identify compounds that synergize with EFHD1 loss. Additional investigations may involve mitochondrial membrane potential assessment via JC-1 staining and cell viability assays like MTT. Researchers can also validate gene disruption by Western blot and RT-qPCR. For further technical details on these CRISPR/Cas9-edited Huh-7 EFHD1 knockout polyclonal cells, please contact Ascent Research.
